Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer.

Brian M SlomovitzAnca Chelariu-Raicu Kathleen M SchmelerKaren H LuDavid M GershensonJudith WolfRobert L Coleman

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)

In this cohort, single agent therapy with cetuximab was well tolerated and had a 15% clinical benefit response. Further studies are required to better identify patients who may respond to this treatment.

Keyphrases

endometrial cancer
metastatic colorectal cancer
multiple sclerosis
locally advanced
wild type
squamous cell carcinoma
stem cells
mesenchymal stem cells
radiation therapy
study protocol
placebo controlled